JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Epidemiology and Antimicrobial Resistance of Nosocomial Pathogens in Intensive Care Units

Deborah Persis Joshua Kothapalli*[1], Vijay Anand Kada[2]

[1]*Department of Microbiology, Aditya Degree and PG College (A), Kakinada, Andhra Pradesh, India*
[2]*Department of Pharmacy Practice, Pydah College of Pharmacy, Patavala, Andhra Pradesh, India*

Publication history: Received on 2nd February 2026; Revised on 13th March 2026; Accepted on 15th March 2026

Article DOI: 10.69613/3v6nqz71

Abstract: Nosocomial infections contribute to the complexity of critical care, leading to substantial increases in patient morbidity, mortality, and healthcare expenditure. The intensive care unit (ICU) serves as a reservoir for highly virulent and multidrug-resistant (MDR) organisms, a phenomenon caused by the frequent use of invasive medical devices, the physiological vulnerability of critically ill patients, and the selective pressure exerted by broad-spectrum antimicrobial therapy. Gram-negative bacilli, particularly *Acinetobacter baumannii, Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*, dominate the microbiological environment of the ICU, frequently manifesting as ventilator-associated pneumonia and bloodstream infections. Simultaneously, Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) remain persistent threats. The evolution of resistance is characterized by the production of extended-spectrum beta-lactamases (ESBLs), carbapenemases, and the formation of robust biofilms, which collectively render conventional therapeutic regimens ineffective. High rates of carbapenem resistance among Enterobacteriaceae and non-fermenting bacilli requires the use of last-resort antibiotics, further narrowing the window for successful clinical intervention. Effective management relies on the implementation of stringent infection control procedures, strong antimicrobial stewardship, and continuous local epidemiological surveillance. Solving the rising concern of antimicrobial resistance requires a shift toward precision diagnostics and novel therapeutic regimens to reduce the impact of healthcare-associated infections in the most vulnerable patient populations.

Keywords: Nosocomial infections; Intensive care unit; Antimicrobial resistance; Multidrug-resistant organisms; Healthcare-associated infections

1. Introduction

Nosocomial infections, often categorized as healthcare-associated infections (HAIs), remain a formidable obstacle in the management of critically ill patients. These infections are defined as pathological conditions arising from infectious agents or their toxins that were neither present nor in the incubation phase upon hospital admission [1]. Within the hospital hierarchy, the intensive care unit (ICU) exhibits the highest prevalence of HAIs, with rates often three to five times higher than those observed in general medical or surgical wards [2]. This high incidence is primarily attributable to the severity of the underlying illness, the need for invasive life-sustaining equipment, and the unique microenvironment of the ICU, which facilitates the selection of highly resistant microbial clones [3].

The global trend of ICU-acquired infections is increasingly defined by the rapid dissemination of antimicrobial resistance (AMR), a trend that complicates empirical therapy and elevates the risk of therapeutic failure [4]. The pathogens most frequently implicated in these infections often belong to the "ESKAPE" group, an acronym representing *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species [5]. These organisms are characterized by their ability to "escape" the bactericidal effects of conventional antibiotics through a variety of genetic and biochemical mechanisms [6].

The presence of a nosocomial infection in the ICU is directly correlated with adverse clinical outcomes, including prolonged mechanical ventilation, extended duration of hospital stays, and higher rates of septic shock [7]. Beyond the clinical implications, the economic burden on healthcare systems is substantial, involving increased costs for laboratory diagnostics, specialized nursing care, and expensive last-resort antimicrobial agents [8]. Establishing an accurate epidemiological profile of local pathogens and their susceptibility patterns is therefore a fundamental requirement for the development of effective clinical guidelines and the preservation of existing antibiotic efficacy [9].

---

[*] Corresponding author: Deborah Persis Joshua Kothapalli

2. Clinical Manifestations of ICU-Acquired Infections

The ICU environment requires the use of various invasive technologies that inadvertently bypass the body's natural anatomical barriers, providing direct portals for microbial entry and subsequent colonization.

2.1. Respiratory Tract Infections

Ventilator-associated pneumonia (VAP) is the most frequent HAI in the ICU, typically occurring in patients who have been intubated for at least 48 hours [10]. The pathogenesis involves the micro-aspiration of oropharyngeal secretions contaminated by pathogenic bacteria that have colonized the subglottic region. Early-onset VAP (occurring within the first four days of intubation) is often caused by antibiotic-sensitive bacteria, whereas late-onset VAP is frequently associated with multidrug-resistant pathogens such as *Acinetobacter baumannii* and *Pseudomonas aeruginosa* [11]. The presence of VAP is associated with significant delays in weaning from mechanical ventilation and is a primary driver of antibiotic consumption in critical care units [12].

Table 1. ICU-Associated Infections and Their Predominant Risk Factors

Infection Type	Primary Risk Factors	Common Complications
Ventilator-Associated Pneumonia (VAP)	Prolonged intubation, supine positioning, micro-aspiration, failed sedation holidays	Acute Respiratory Distress Syndrome (ARDS), difficult weaning
Central Line-Associated Bloodstream Infection (CLABSI)	Duration of catheterization, femoral insertion site, lack of maximal sterile barriers	Septic shock, endocarditis, metastatic seeding
Catheter-Associated Urinary Tract Infection (CAUTI)	Indwelling duration, break in sterile drainage system, female gender	Secondary bacteremia, urosepsis, pyelonephritis
Surgical Site Infection (SSI)	Wound contamination, inadequate prophylaxis, emergency surgery, poorly controlled diabetes	Abscess formation, wound dehiscence, sepsis

2.2. Bloodstream and Cardiovascular Infections

Central line-associated bloodstream infections (CLABSIs) are critical complications arising from the use of central venous catheters. Pathogens typically migrate along the external surface of the catheter or are introduced through the catheter hub during manipulation [13]. These infections provide direct systemic access for virulent organisms, often leading to rapid clinical deterioration and secondary organ failure. Biofilm formation on the catheter tip is a hallmark of these infections, protecting the pathogens from both the host immune response and systemic antibiotics, which often necessitates the removal of the device to achieve clinical cure [14].

2.3. Urinary Tract Infections

Catheter-associated urinary tract infections (CAUTIs) are primarily caused by the prolonged use of indwelling urinary catheters [15]. Although often perceived as less acute than pneumonia or sepsis, CAUTIs act as a silent reservoir for MDR organisms, facilitating their spread within the ICU through horizontal transmission. The risk of bacteriuria increases cumulatively for each day the catheter remains in place, and the presence of a biofilm on the catheter surface makes these infections particularly difficult to eradicate without device replacement [11].



Figure 1. The Transmission Cycle of Nosocomial Pathogens

3. Predominant Pathogens in the Critical Care Areas

The microbiological profile of the ICU has shifted over recent decades, with Gram-negative organisms increasingly displacing Gram-positive cocci as the primary cause of severe infections.

3.1. Gram-Negative Bacilli

3.1.1. Acinetobacter baumannii

Acinetobacter baumannii is a non-fermenting, aerobic Gram-negative bacillus known for its remarkable environmental resilience and its ability to survive on dry surfaces for weeks [12]. It is a frequent cause of VAP and bloodstream infections in the ICU. The clinical challenge posed by *A. baumannii* lies in its rapid acquisition of resistance genes, leading to the emergence of carbapenem-resistant *A. baumannii* (CRAB) strains [14]. These strains are often susceptible only to polymyxins or newer agents like tigecycline, leaving clinicians with very few therapeutic options.

3.1.2. Klebsiella pneumoniae

Klebsiella pneumoniae is a common inhabitant of the human gastrointestinal tract that acts as a potent opportunistic pathogen in the ICU. It is frequently implicated in severe pneumonia, urinary tract infections, and neonatal sepsis [1]. The prevalence of carbapenem-resistant *Enterobacteriaceae* (CRE), specifically *K. pneumoniae* carbapenemase (KPC)-producing strains, has reached critical levels in many regions [14]. The mortality associated with KPC-producing *K. pneumoniae* bloodstream infections remains alarmingly high, often exceeding 40%.

3.1.3. Pseudomonas aeruginosa

Pseudomonas aeruginosa utilizes an array of virulence factors, including pili, flagella, and secreted toxins, to establish infections in compromised hosts [5]. Its intrinsic resistance to many antibiotic classes, combined with its ability to form dense biofilms on medical equipment, makes it a persistent threat in the ICU. MDR strains of *P. aeruginosa* are particularly prevalent in patients with chronic lung disease or those who have received multiple courses of prior antibiotics [11].



Figure 2. Classification of Common ICU Pathogens

3.1.4. Escherichia coli

While *Escherichia coli* is a frequent cause of community-acquired infections, its role in the ICU is significant, particularly in the context of urosepsis and intra-abdominal infections [8]. The widespread dissemination of extended-spectrum beta-lactamases (ESBLs) among *E. coli* isolates has rendered third-generation cephalosporins ineffective, driving the increased use of carbapenems as first-line therapy, which in turn fuels the cycle of resistance [8].

Table 2. Common Nosocomial Pathogens and Typical Clinical Presentations

Pathogen	Gram Stain	Primary Clinical Manifestation	Environmental Niche
Acinetobacter baumannii	Negative	VAP, Bacteremia, Wound infections	Hospital surfaces, ventilators, sinks
Klebsiella pneumoniae	Negative	Pneumonia, UTI, Neonatal sepsis	Gastrointestinal tract, medical staff hands
Pseudomonas aeruginosa	Negative	VAP, Sepsis, Post-burn infections	Humidifiers, taps, ventilator circuits
Staphylococcus aureus	Positive	Skin infections, Bacteremia, VAP	Nares, skin, medical equipment
Enterococcus species	Positive	UTI, Endocarditis, Intra-abdominal sepsis	Intestinal flora, contaminated surfaces

3.2. Gram-Positive Cocci

3.2.1. Staphylococcus aureus

Staphylococcus aureus remains a leading cause of skin, soft tissue, and bloodstream infections. Methicillin-resistant *Staphylococcus aureus* (MRSA) is characterized by the presence of the *mecA* gene, which encodes an altered penicillin-binding protein (PBP2a), conferring resistance to almost all beta-lactam antibiotics [4]. MRSA outbreaks in the ICU are often linked to breaches in hand hygiene or the use of contaminated shared medical equipment [9].

3.2.2. Enterococcus Species

Enterococcus faecalis and *Enterococcus faecium* are increasingly recognized as significant ICU pathogens, particularly in patients with prolonged hospitalization and prior exposure to cephalosporins [5]. Vancomycin-resistant *Enterococcus* (VRE) is a major concern due to its ability to transfer resistance determinants to other Gram-positive organisms. VRE infections are often difficult to treat, requiring the use of newer agents like linezolid or daptomycin [12].

4. Mechanisms of Antimicrobial Resistance

The acquisition of resistance in the ICU is a sophisticated biological process involving both intrinsic genetic traits and the horizontal acquisition of resistance determinants through plasmids, transposons, and integrons [12].

4.1. Enzymatic Degradation and Modification

4.1.1. Beta-Lactamase Production

The production of beta-lactamase enzymes is the primary mechanism of resistance among Gram-negative bacteria. Extended-spectrum beta-lactamases (ESBLs), predominantly of the CTX-M, TEM, and SHV families, hydrolyze third-generation cephalosporins and monobactams [8]. Of greater concern in the ICU is the proliferation of carbapenemases, such as *Klebsiella pneumoniae* carbapenemase (KPC), New Delhi metallo-beta-lactamase (NDM), and OXA-48-like enzymes. these enzymes effectively neutralize almost all available beta-lactam antibiotics, including carbapenems, which were previously considered the definitive treatment for MDR infections [14].



Figure 3. Molecular Mechanisms of Antimicrobial Resistance

4.1.2. Aminoglycoside-Modifying Enzymes

Resistance to aminoglycosides often occurs through the production of enzymes that acetylate, adenylate, or phosphorylate the antibiotic molecule. These modifications prevent the drug from binding to its ribosomal target, thereby neutralizing its bactericidal effect [12].

4.2. Alterations in Membrane Permeability and Efflux

4.2.1. Porin Loss

Gram-negative bacteria control the entry of molecules through specialized protein channels called porins. The down-regulation or loss of specific porins, such as OmpK35/36 in *K. pneumoniae* or OprD in *P. aeruginosa*, significantly reduces the intracellular concentration of carbapenems, often acting synergistically with beta-lactamase production to achieve high-level resistance [14].

4.2.2. Active Efflux Systems

Multidrug efflux pumps, such as the RND-family pumps (e.g., MexAB-OprM in *P. aeruginosa* and AdeABC in *A. baumannii*), can actively expel a wide range of structurally unrelated antibiotics, including fluoroquinolones, tetracyclines, and beta-lactams, from the periplasmic space to the external environment [11].

4.3. Target Site Modification

Pathogens may alter the molecular structure of the antibiotic's target to evade detection. Examples include the methylation of the 23S rRNA by *erm* genes, conferring resistance to macrolides and lincosamides, or mutations in the Quinolone Resistance-Determining Regions (QRDR) of DNA gyrase and topoisomerase IV, which lead to high-level fluoroquinolone resistance [12].

4.4. Biofilm Architecture and Persistence

In the ICU, biofilm formation on indwelling devices such as endotracheal tubes and central venous catheters represents a formidable barrier. The extracellular polymeric substance (EPS) matrix limits antibiotic penetration, while the presence of "persister cells" metabolically inactive variants allows the population to survive high concentrations of bactericidal agents [9].

Table 3. Mechanisms of Resistance in High-Priority ICU Pathogens

Mechanism	Molecular Basis	Representative Pathogens	Impact on Therapy
Enzymatic Hydrolysis	ESBLs (CTX-M), Carbapenemases (KPC, NDM-1)	*K. pneumoniae*, *E. coli*, *P. aeruginosa*	Resistance to cephalosporins and carbapenems
Target Site Mutation	*mecA* gene (PBP2a), *vanA/vanB* clusters	*S. aureus* (MRSA), *Enterococcus* (VRE)	Resistance to methicillin and vancomycin
Active Efflux	MexAB-OprM, AdeABC systems	*P. aeruginosa*, *A. baumannii*	Cross-resistance to multiple antibiotic classes
Porin Loss	Loss of OmpK35/36, OprD downregulation	*K. pneumoniae*, *P. aeruginosa*	Reduced entry of carbapenems into the cell

5. Phenotypic Resistance Patterns in ICU Isolates

Current surveillance data indicate a worsening trend in the susceptibility profiles of the most common ICU pathogens [15].

5.1. Carbapenem-Resistant Organisms

The rise of Carbapenem-Resistant *Enterobacteriaceae* (CRE) and Carbapenem-Resistant *Acinetobacter baumannii* (CRAB) represents a critical public health threat. In many ICUs, resistance rates to imipenem and meropenem exceed 50% for *Acinetobacter* species [14]. This shift necessitates the use of polymyxins (colistin) or newer cephalosporin-beta-lactamase inhibitor combinations (e.g., ceftazidime-avibactam), although resistance to these agents is also emerging [15].

5.2. Multidrug and Extensively Drug-Resistant Profiles

5.2.1. Acinetobacter baumannii

Often displays an extensively drug-resistant (XDR) phenotype, showing sensitivity only to one or two classes, typically polymyxins or tetracyclines [12].

5.2.2. Pseudomonas aeruginosa

Frequently exhibits resistance to aminoglycosides and fluoroquinolones, complicating the management of VAP [11].

5.2.3. Enterococcus species

High rates of vancomycin resistance (VRE) among *E. faecium* isolates are observed, particularly in ICUs with high cephalosporin utilization [5].

6. Factors Causing Antimicrobial Resistance in Critical Care

The high density of antibiotic use and the unique physical environment of the ICU contribute to the selection and transmission of resistant strains.

6.1. Antimicrobial Selective Pressure

The frequent administration of broad-spectrum empirical therapy, often without subsequent de-escalation, eliminates susceptible microflora and allows resistant sub-populations to expand [11]. Delayed initiation of appropriate therapy is linked to poor outcomes, yet prolonged inappropriate use accelerates the "vicious cycle" of resistance [6].

6.2. Environmental Persistence and Cross-Transmission

ICU surfaces, including bed rails, monitors, and infusion pumps, act as reservoirs for pathogens like MRSA and *Acinetobacter* [12]. Inadequate adherence to hand hygiene protocols and environmental disinfection allows these organisms to be transferred between patients via the hands of healthcare workers or contaminated mobile equipment.

6.3. Host Factors and Device Utilization

Critically ill patients possess impaired cellular immunity and frequently undergo procedures that disrupt the integrity of the skin and mucosal surfaces. The presence of a "foreign body" (e.g., a catheter or ventilator tube) provides a scaffold for microbial colonization and subsequent biofilm-mediated resistance [9].

6.4. Operational and Structural Deficiencies

Understaffing, high patient-to-nurse ratios, and overcrowding in the ICU environment are strongly associated with increased transmission rates of MDR organisms. Without adequate resources for isolation and cohorting, the containment of an outbreak becomes exceedingly difficult

7. Clinical Consequences

The occurrence of nosocomial infections in the ICU is a primary determinant of adverse clinical outcomes. The presence of multidrug-resistant (MDR) pathogens significantly complicates the clinical course of critically ill patients [6].

7.1. Morbidity and Mortality Escalation

Infections caused by MDR organisms are associated with significantly higher mortality rates compared to those caused by susceptible strains. For instance, bloodstream infections involving carbapenem-resistant *Enterobacteriaceae* (CRE) carry mortality rates exceeding 40% in some cohorts [8]. The physiological stress of sepsis, combined with the limited efficacy of available salvage therapies, often leads to multi-organ dysfunction syndrome (MODS), further reducing the probability of survival [1].

7.2. Healthcare Utilization and Economic Burden

Patients with ICU-acquired infections require a disproportionate amount of hospital resources. This includes extended duration of mechanical ventilation, increased necessity for renal replacement therapy, and significantly longer ICU and total hospital stays [2]. From an economic perspective, the costs associated with specialized diagnostics, expensive second- and third-line antimicrobials, and the intensive nursing care required for isolation protocols place a massive strain on healthcare budgets [7].



Figure 4. Therapeutic Escalation for Extensively Drug-Resistant (XDR) Isolates

Table 4. Comparative Impact of Susceptible vs. Resistant Infections on ICU Outcomes

Outcome Metric	**Susceptible Infection**	**Multi-Drug Resistant (MDR) Infection**	**Estimated Percentage Increase**
Attributable Mortality	10% - 15%	30% - 50%	200% - 300%
Mean Duration of ICU Stay	5 - 7 Days	14 - 21 Days	180% - 200%
Healthcare Cost per Episode	Moderate	High (Expensive agents + Isolation)	150% - 250%
Likelihood of Septic Shock	Lower	Higher	Significant

---

8. Mitigation and Infection Control Frameworks

Controlling the dissemination of resistant pathogens requires a multi-faceted approach that integrates behavioral changes with structural improvements.

8.1. Hand Hygiene and Contact Precautions

Rigorous adherence to hand hygiene remains the cornerstone of infection prevention. The "Five Moments for Hand Hygiene" protocol serves as a critical barrier against the cross-transmission of pathogens between patients and the environment [9]. For patients colonized with MDR organisms, contact precautions including the use of dedicated gowns and gloves are essential to contain the spread of high-risk clones [11].

8.2. Antimicrobial Stewardship Programs (ASP)

Antimicrobial stewardship involves the systematic effort to optimize antibiotic use to improve patient outcomes while minimizing the development of resistance [11]. Effective ASPs in the ICU focus on several key interventions:

- Empirical Therapy Optimization: Aligning initial treatment with local antibiogram data to ensure early appropriate therapy [10].
- De-escalation: Transitioning from broad-spectrum to narrow-spectrum agents as soon as microbiological results are available [11].
- Dose Optimization: Utilizing pharmacokinetic and pharmacodynamic (PK/PD) principles to ensure adequate drug exposure in physiologically altered ICU patients [11].



Figure 5. Antimicrobial Stewardship process in the ICU

8.3. Bundle-Based Care for Invasive Devices

The implementation of "care bundles" a small set of evidence-based practices has proven highly effective in reducing device-associated infections. Ventilator bundles (e.g., head-of-bed elevation, daily sedation vacations) and central line bundles (e.g., maximal sterile barrier precautions, chlorhexidine skin antisepsis) have led to significant reductions in VAP and CLABSI rates globally [13].

Table 5. Components of Antimicrobial Stewardship and Infection Bundles (To be included in Section 8)

Intervention Category	Actionable Items	Desired Outcome
Antimicrobial Stewardship	Pharmacodynamic dosing, de-escalation, duration limit	Reduced selection pressure, improved cure rates
Ventilator Care Bundle	Head-of-bed elevation (30-45°), subglottic suctioning	Reduced VAP incidence, early extubation
Central Line Bundle	Chlorhexidine skin prep, daily assessment of necessity	Eradication of CLABSI, reduced device days
Standard Precautions	Universal hand hygiene, alcohol-based hand rubs	Interruption of horizontal transmission

---

9. Current Therapeutic Horizons

Addressing the persistent challenge of ICU pathogens requires moving beyond traditional methods toward more advanced technological solutions.

9.1. Rapid Molecular Diagnostics

The transition from culture-based methods to rapid molecular diagnostics, such as Multiplex PCR and Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) mass spectrometry, allows for the identification of pathogens and resistance markers within hours rather than days [14]. This speed is crucial for the timely initiation of targeted therapy and the early implementation of isolation measures.

Table 6. Comparison of Conventional and Emerging Diagnostic Methods

Modality	Turnaround Time (TAT)	Advantages	Primary Limitation
Traditional Culture	48 - 72 Hours	Defines phenotypic MIC, low cost	Slow, poor yield if pre-treated
MALDI-TOF MS	< 1 Hour (from culture)	Rapid species identification	Requires prior culture growth
Multiplex PCR	2 - 4 Hours	Detects resistance genes (KPC, NDM)	Does not distinguish live/dead bacteria
AI Surveillance	Real-time	Early warning for potential outbreaks	Requires integrated EHR systems

9.2. Precision Medicine and Alternative Therapies

Advancements in genomics and bioinformatics are paving the way for personalized antimicrobial therapy, tailored to both the pathogen's resistance profile and the patient's individual drug metabolism [15]. Research on alternative treatments, such as bacteriophage therapy, monoclonal antibodies, and microbiota restoration through fecal microbiota transplantation (FMT), offers potential avenues for managing pan-drug-resistant infections that are currently untreatable [14].

9.3. Artificial Intelligence in Surveillance

Artificial intelligence (AI) and machine learning algorithms are being developed to predict ICU infection outbreaks before they manifest clinically. These systems can identify high-risk patients and subtle environmental changes, allowing for preemptive infection control interventions by analyzing real-time data from electronic health records [15].

10. Conclusion

Nosocomial infections in the intensive care unit are a persistent and evolving threat to patient safety, characterized by a microbiological shift toward highly resistant Gram-negative organisms. The combination of host vulnerability, invasive technology, and the selection pressure of broad-spectrum antibiotics have created an environment where traditional therapeutic options are rapidly diminishing. The rise of carbapenem resistance and biofilm-mediated persistence necessitates a transition from reactive treatment to proactive prevention. Success in mitigating the impact of these infections depends on a rigorous commitment to infection control, the intelligent application of antimicrobial stewardship, and the adoption of rapid diagnostic technologies. A multidisciplinary approach that combines clinical vigilance with scientific innovation is required to safeguard the efficacy of our antimicrobial armamentarium and improve the prognosis of the critically ill.

References

[1] Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-2329.

[2] Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of healthcare-associated infections. New England Journal of Medicine. 2014;370(13):1198-1208.

[3] World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015.

[4] Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections. Infection Control & Hospital Epidemiology. 2013;34(1):1-14.

[5] Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12.

[6] Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-474.

[7] Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. Journal of Infectious Diseases. 2008;197(8):1079-1081.

[8] Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Clinical Infectious Diseases. 2007;44(6):839-846.

[9] Centers for Disease Control and Prevention (CDC). Healthcare-associated infections (HAIs). Atlanta: CDC; 2023.

[10] Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100. 33rd ed. Wayne, PA: CLSI; 2023.

[11] De Waele JJ, Akova M, Antonelli M, Canton R, Carlet J, De Backer D, et al. Antimicrobial resistance and antibiotic stewardship programs in intensive care units. Intensive Care Medicine. 2018;44(2):189-196.

[12] Basak S, Singh P, Rajurkar M. Multidrug resistant and extensively drug resistant bacteria: A study. Journal of Pathogens. 2016;2016:4065603.

[13] Nair GB, Niederman MS. Ventilator-associated pneumonia: Present understanding and ongoing debates. Intensive Care Medicine. 2015;41(1):34-48.

[14] Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant Gram-negative bacteria. Frontiers in Cellular and Infection Microbiology. 2022;12:823684.

[15] Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet. 2022;399(10325):629-655.